Gwen Orilio's Cancer Journey: Gwen Orilio was diagnosed with stage-four lung cancer at 31, which had spread to her eye, leading her to forgo planning for retirement.
Survival Beyond Expectations: Despite her grim prognosis, Orilio has survived for ten years with metastatic cancer and continues to live with the disease.
NUVL
$102.63+Infinity%1D
Analyst Views on NUVL
Wall Street analysts forecast NUVL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVL is 139.60 USD with a low forecast of 105.00 USD and a high forecast of 158.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast NUVL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVL is 139.60 USD with a low forecast of 105.00 USD and a high forecast of 158.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 104.970
Low
105.00
Averages
139.60
High
158.00
Current: 104.970
Low
105.00
Averages
139.60
High
158.00
Truist
Buy
initiated
$140
2025-11-24
Reason
Truist
Price Target
$140
2025-11-24
initiated
Buy
Reason
Truist initiated coverage of Nuvalent with a Buy rating and $140 price target. Nuvalent is emerging as a disruptive precision oncology company poised for commercial transformation by 2026 with two lead candidates approaching potential approval in oncogene-driven non-small cell lung cancer, the analyst tells investors in a research note.
Guggenheim
Brad Canino
Buy
maintain
$125 -> $155
2025-11-18
Reason
Guggenheim
Brad Canino
Price Target
$125 -> $155
2025-11-18
maintain
Buy
Reason
Guggenheim analyst Brad Canino raised the firm's price target on Nuvalent to $155 from $125 and keeps a Buy rating on the shares. The positive neladalkib pivotal data lead the firm to "fully de-risk" its second-to-third line ALK+ NSCLC odds of success estimate and increase its first-line odds to 75%, the analyst tells investors.
Baird
Baird
Outperform
maintain
$112 -> $158
2025-11-18
Reason
Baird
Baird
Price Target
$112 -> $158
2025-11-18
maintain
Outperform
Reason
Baird raised the firm's price target on Nuvalent to $158 from $112 and keeps an Outperform rating on the shares. The firm said its pivotal data in 2L+ALK+NSLC shows strong durability.
Goldman Sachs
Buy
maintain
$120 -> $135
2025-11-18
Reason
Goldman Sachs
Price Target
$120 -> $135
2025-11-18
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Nuvalent to $135 from $120 and keeps a Buy rating on the shares. Neladalkib continues to show best-in-class efficacy vs. other anaplastic lymphoma kinase tyrosine kinase inhibitors in refractory patients, the analyst tells investors in a research note. The firm continues to believe Nuvalent could seek NCCN guideline recommendations for neladalkib in 1L ALK+ NSCLC ahead of its approval there following a similar strategy for zidesamtinib in 1L ROS1+ NSCLC.
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
